Inovio Pharmaceuticals Inc vs Abrdn Physical Platinum Shares ETF — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while Abrdn Physical Platinum Shares ETF trades at $14.74. The key difference: Abrdn Physical Platinum Shares ETF is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| INO | PPLT | |
|---|---|---|
Market Cap | $89.27M | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $2.87 | $25.23 |
52-Week Low | $1.05 | $11.78 |
Enterprise Value | $60.28M | — |
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
PPLT, the abrdn Physical Platinum Shares ETF, trades at $14.47, down 0.21% on the day, amid a predominantly bearish technical signal with moving averages indicating strong selling pressure. The fund, which holds physical platinum, has seen significant volatility, with recent news highlighting its underperformance compared to gold and silver. A 10-for-1 stock split is scheduled for May 2026, which will adjust the share count without altering the fund's net asset value.
The outlook for PPLT is cautious, with technical indicators leaning bearish and sentiment mixed after a substantial rally. Investment opportunity hinges on a potential catch-up trade if platinum gains favor, but risks include commodity price swings and the ETF's lack of dividends, which may deter income-focused investors.
Trailing returns across standard periods
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →PPLT is a physically-backed ETF designed to track the spot price of platinum, less the Trust's expenses. It holds physical platinum bullion in secure vaults, providing investors with a liquid and cost-effective way to access the platinum market without the logistical challenges of direct ownership.
Read more on PPLT →